Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro

Drug Metabolism and Disposition

Volumn 40, Issue 4, 2012, Pages 655-661

  Amundsen, Rune ^a   Åsberg, Anders ^a   Ohm, Ingrid Kristine ^a   Christensen, Hege ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MIDAZOLAM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TACROLIMUS;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HYDROXYLATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; LIVER MICROSOME; MICROSOME; NONHUMAN; PRIORITY JOURNAL;

CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICROSOMES, LIVER; MIDAZOLAM; NONLINEAR DYNAMICS; SUBSTRATE SPECIFICITY; TACROLIMUS; TIME FACTORS;

HEXAPODA;

EID: 84858412666     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.043018     Document Type: Article

References (40)

1. Åsberg A (2003) Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 63:367-378.
2. Åsberg A, Christensen H, Hartmann A, Carlson E, Molden E, and Berg KJ. (1999) Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients. Eur J Clin Pharmacol 55:383-387. (Pubitemid 29344082)
3. Amundsen R, Christensen H, Zabihyan B, and Asberg A (2010) Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos 38:1499-1504.
4. Bachmann KA and Lewis JD (2005) Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39:1064-1072. (Pubitemid 40695974)
5. Campana C, Regazzi MB, Buggia I, and Molinaro M (1996) Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet 30:141-179.
6. Christensen H, Mathiesen L, Postvoll LW, Winther B, and Molden E (2009) Different enzyme kinetics of midazolam in recombinant CYP3A4 microsomes from human and insect sources. Drug Metab Pharmacokinet 24:261-268.
7. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, and Thummel KE (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836-847.
8. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, and Kuypers DR (2011) In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. Clin Pharmacol Ther 90:414-422.
9. Falck P, Vethe NT, Asberg A, Midtvedt K, Bergan S, Reubsaet JL, and Holdaas H (2008) Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 23:1048-1053. (Pubitemid 351767545)
10. Galetin A, Burt H, Gibbons L, and Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166-175. (Pubitemid 43042658)
11. Galetin A, Gertz M, and Houston JB (2010) Contribution of intestinal cytochrome P450- mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet 25:28-47.
12. Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
13. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, and Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133-143. (Pubitemid 28423848)
14. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355-1370.
15. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
16. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, and Christians U (1999) Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27:173-179.
17. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, and Backman JT (2005) Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 78:388-399. (Pubitemid 41393674)
18. Kanamitsu S, Ito K, and Sugiyama Y (2000) Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336-343. (Pubitemid 30225138)
19. Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, and Sugiyama Y (2008) The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res 25:1891-1901.
20. Lecointre K, Furlan V, and Taburet AM (2002) In vitro effects of tacrolimus on human cytochrome P450. Fundam Clin Pharmacol 16:455-460. (Pubitemid 35463881)
21. Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, and Maes BD (2005) Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 5:2236-2243. (Pubitemid 41648471)
22. Mignat C (1997) Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 16:267-278.
23. Neuvonen PJ, Niemi M, and Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-581. (Pubitemid 44908269)
24. Niwa T, Yamamoto S, Saito M, Shiraga T, and Takagi A (2007) Effect of cyclosporine and tacrolimus on cytochrome P450 activities in human liver microsomes. Yakugaku Zasshi 127:209-216. (Pubitemid 46089919)
25. Nooter K, Sonneveld P, Janssen A, Oostrum R, Boersma T, Herweijer H, Valerio D, Hagemeijer A, and Baas F (1990) Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. Int J Cancer 45:626-631. (Pubitemid 20146119)
26. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255. (Pubitemid 46148737)
27. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348. (Pubitemid 41832613)
28. Paine MF, Davis CL, Shen DD, Marsh CL, Raisys VA, and Thummel KE (2000) Can oral midazolam predict oral cyclosporine disposition? Eur J Pharm Sci 12:51-62.
29. Picard N, Djebli N, Sauvage FL, and Marquet P (2007) Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos 35:350-355.
30. Polasek TM and Miners JO (2007) In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 3:321-329. (Pubitemid 47316027)
31. Polasek TM, Sadagopal JS, Elliot DJ, and Miners JO (2010) In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Eur J Clin Pharmacol 66:275-283.
32. Rostami-Hodjegan A and Tucker G (2004) 'In silico' simulations to assess the 'in vivo'consequences of 'in vitro' metabolic drug- drug interactions. Drug Discov Today Technol 1:441-448. (Pubitemid 40186348)
33. Shiraga T (1999) Oxidative metabolism of tacrolimus and its metabolite by human cytochrome P450 3A subfamily. Drug Metab Pharmacokinet 14:277-285.
34. Venkataramanan R, Jain A, Warty VS, Abu-Elmagd K, Alessiani M, Lever J, Krajak A, Flowers J, Mehta S, and Zuckerman S (1991) Pharmacokinetics of FK 506 in transplant patients. Transplant Proc 23:2736-2740.
35. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660. (Pubitemid 38668158)
36. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, and Wood AJ.(1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59:3944-3948. (Pubitemid 29393559)
37. Wang YH, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266. (Pubitemid 38176944)
38. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2005) Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. Eur J Pharm Sci 26:334-340. (Pubitemid 41278639)
39. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684. (Pubitemid 47578116)
40. Zhou SF, Xue CC, Yu XQ, Li C, and Wang G (2007) Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29:687-710. (Pubitemid 350190847)